Delivery Order 75D30124D20079-75D30124F00002
Award Date
9/27/24
Potential Completion Date
9/26/25
Potential Value
$775K
Federal Agency
CDC Pittsburgh
Awardee
Ginkgo Bioworks, Inc.
Ultimate Awardee
Not listed
NAICS Category
621511 - Medical Laboratories
PSC Category
Q301 - Reference Laboratory Testing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Time and Materials
Place of Performance
Boston, MA 02210, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
5
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for a delivery order under the "Test Surge and Data Sharing Multiple Award IDIQ" issued by the Centers for Disease Control and Prevention (CDC). The prime contractor is Ginkgo Bioworks, Inc., a biotechnology company based in Boston, Massachusetts. The contract has a ceiling value of $449,761.53 and a completion date of May 15, 2025. It is a time and materials contract type, with no set-aside designation. The contract leverages Ginkgo Bioworks' expertise...
This $50,216,772.13 Firm Fixed Price Delivery Order contract was awarded to Ginkgo Bioworks, Inc., a biotechnology company based in Boston, Massachusetts. The contract is for test surge and data sharing services under a larger Indefinite Delivery/Indefinite Quantity (IDIQ) vehicle held with the Centers for Disease Control and Prevention (CDC). The IDIQ has a total ceiling value of $118 million and an ultimate completion date of September 5, 2029. Ginkgo Bioworks has previously provided...
The U.S. Centers for Disease Control and Prevention (CDC) awarded a $85,741,227.24 Firm Fixed Price Definitive Contract to Ginkgo Bioworks, Inc., a biotechnology company in Boston, Massachusetts, for a Traveler-Based Genomic Surveillance Program. The contract has an ultimate completion date of March 21, 2028 and was not set aside for a specific business category. This contract appears to build on Ginkgo Bioworks' previous work with the CDC on COVID-19 genomic testing and surveillance at major...
This is a $1,205,149.24 Firm Fixed Price contract awarded by the Centers for Disease Control and Prevention (CDC) to Ginkgo Bioworks, Inc., a biotechnology company based in Boston, Massachusetts. The contract, titled "TRAVELER-BASED GENOMIC SURVEILLANCE," is for the provision of biotechnology services to support the CDC's public health monitoring and emergency response initiatives. The contract has an ultimate completion date of September 19, 2024 and was awarded on August 26, 2024....
The Centers for Disease Control and Prevention (CDC) awarded a $76,575,638.04 firm-fixed-price contract to Ginkgo Bioworks, Inc., a Boston-based biotechnology company, to conduct genomic testing and surveillance of SARS-CoV-2 at five major U.S. international airports. The contract, which runs through March 21, 2025, requires Ginkgo Bioworks to collect a minimum of 483,000 biological samples per year from international travelers and perform on-site reverse transcription polymerase chain...
The U.S. Centers for Disease Control and Prevention (CDC) awarded an Indefinite Delivery Indefinite Quantity (IDIQ) contract to Quest Diagnostics Incorporated, a provider of diagnostic information services, for a "Test Surge and Data Sharing" program. The $493,118 contract has a period of performance through September 2025 and is a time and materials type contract. This IDIQ vehicle allows the CDC to procure clinical laboratory testing and analysis services from Quest Diagnostics on an...
This is a $6,631,042.24 Indefinite Delivery Indefinite Quantity (IDIQ) contract awarded to Quest Diagnostics Incorporated by the Centers for Disease Control and Prevention (CDC) to provide test surge and data sharing services. The contract has an ultimate completion date of September 26, 2029. This IDIQ contract is part of the broader "Test Surge and Data Sharing Multiple Award IDIQ" and does not have a set-aside designation. Under this contract, Quest Diagnostics will provide a...
The U.S. Centers for Disease Control and Prevention (CDC) awarded a firm-fixed-price delivery order to Aegis Sciences Corporation, a for-profit organization, to provide Test Surge and Data Sharing services. This order was placed under a multiple-award indefinite-delivery, indefinite-quantity (IDIQ) contract with a total ceiling value of $2,427,648.50 and a period of performance through September 26, 2029. Aegis, operating out of its laboratory in Nashville, Tennessee, will perform COVID-19...
This is a delivery order awarded by the Centers for Disease Control and Prevention (CDC) to Aegis Sciences Corporation, a forensic toxicology and healthcare laboratory company, for a Test Surge and Data Sharing multiple-award indefinite-delivery, indefinite-quantity (IDIQ) contract. The delivery order, valued at $610,000.00, will task Aegis to provide science-driven drug testing and consulting services, including COVID-19 testing, genomic sequencing, and variant tracking out of its Nashville,...
The National Institutes of Health's National Heart, Lung and Blood Institute awarded Ginkgo Bioworks, Inc. a $6.57 million firm fixed price definitive contract to support the Rapid Acceleration of Diagnostics-Advanced Technology Platforms program. The goal of this program is to increase SARS-CoV-2 testing capacity and throughput by identifying existing testing platforms that can be used for COVID-19 diagnostics. Work will be performed by Ginkgo Bioworks in Boston, Massachusetts over a one year...